Edwards Lifesciences (EW) Payables (2009 - 2026)

Edwards Lifesciences has reported Payables for 18 years, with the latest figure at $210.5 million in Q2 2026.

• On a quarterly basis, Payables rose 29.86% year-over-year to $210.5 million in Q2 2026; TTM through Jun 2026 was $210.5 million, a 29.86% increase from a year earlier, with the FY2025 full-year figure at $227.5 million, up 15.25% from the prior year.
• Payables was $210.5 million for Q2 2026 at Edwards Lifesciences, up from $181.1 million in the prior quarter.
• The five-year high for Payables was $227.5 million in Q4 2025, with the low at $154.9 million in Q3 2022.
• Average Payables over 5 years is $184.2 million, with a median of $183.5 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Payables sank 81.13% in 2022, then climbed 29.86% in 2026.
• Over 5 years, Payables stood at $201.9 million in 2022, then declined by 7.58% to $186.6 million in 2023, then climbed by 5.79% to $197.4 million in 2024, then increased by 15.25% to $227.5 million in 2025, then slipped by 7.47% to $210.5 million in 2026.
• The last three Payables figures came in at $210.5 million (Q2 2026), $181.1 million (Q1 2026), and $227.5 million (Q4 2025), per Business Quant data.